Qiagen and Astellas Pharma to collaborate on companion diagnostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

QIAGEN N.V. and Astellas Pharma Inc. will collaborate to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

Two initial projects in the collaboration focus on oncology and aim to pair Qiagen diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.

The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, giving Astellas access to Qiagen’s assays based on PCR, next generation sequencing and multi-modal testing technologies using liquid and tissue biopsies.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login